ReNeuron Group (RENE) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Apr 2019 09:50 AM
RNS
ReNeuron partners with Fosun Pharma in China
05 Apr 2019 07:00 AM
RNS
ReNeuron to present at UK investor conference
04 Apr 2019 07:00 AM
RNS
Clinical update and conference presentation
28 Mar 2019 02:05 PM
RNS
Second Price Monitoring Extn
28 Mar 2019 02:00 PM
RNS
Price Monitoring Extension
18 Mar 2019 12:00 PM
RNS
Alliance for Regenerative Medicine presentation
18 Mar 2019 07:00 AM
RNS
Retinal clinical trial progresses to next stage
12 Mar 2019 02:30 PM
RNS
Notification of Major Holdings
05 Mar 2019 12:56 PM
RNS
Notification of Major Holdings
05 Mar 2019 07:00 AM
RNS
Notification of Major Holdings
05 Mar 2019 07:00 AM
RNS
Notification of Major Holdings
28 Feb 2019 07:00 AM
RNS
Block Listing Review and Total Voting Rights
20 Feb 2019 07:00 AM
RNS
Positive preliminary data in US retinal trial
31 Jan 2019 07:00 AM
RNS
New exosome production scale-up data presented
24 Jan 2019 07:00 AM
RNS
First patient treated in US stroke trial
04 Jan 2019 07:00 AM
RNS
ReNeuron signs exosome collaboration
14 Dec 2018 07:00 AM
RNS
Interim Results
20 Nov 2018 02:00 PM
RNS
Notification of Interim Results
18 Oct 2018 07:00 AM
RNS
ReNeuron's lead cell line shows further potential
28 Sep 2018 02:16 PM
RNS
Director/PDMR Interest in Shares and Share Options
27 Sep 2018 03:02 PM
RNS
Directors Share Purchases
19 Sep 2018 04:40 PM
RNS
Second Price Monitoring Extn
19 Sep 2018 04:35 PM
RNS
Price Monitoring Extension
19 Sep 2018 07:00 AM
RNS
Business development update
12 Sep 2018 11:40 AM
RNS
Result of AGM
12 Sep 2018 07:00 AM
RNS
AGM Trading Update
31 Aug 2018 07:00 AM
RNS
Block Listing Review and TVR
31 Jul 2018 03:25 PM
RNS
Posting of Annual Report & Notice of AGM
17 Jul 2018 07:00 AM
RNS
Notification of Major Holdings
16 Jul 2018 03:39 PM
RNS
Notification of Major Holdings
16 Jul 2018 07:00 AM
RNS
Notification of Major Holdings
13 Jul 2018 11:50 AM
RNS
Notification of Major Holdings
12 Jul 2018 07:00 AM
RNS
Preliminary Results
11 Jul 2018 07:00 AM
RNS
Signs retinal stem cell exclusivity agreement
04 Jul 2018 02:15 PM
RNS
Notification of Preliminary Results
17 May 2018 07:00 AM
RNS
Capital Markets Event
04 May 2018 07:00 AM
RNS
Exosome data presented at ISCT conference
30 Apr 2018 07:00 AM
RNS
Capital Markets Event and Webcast
19 Apr 2018 07:00 AM
RNS
Wins grant for retinal cell therapy development
10 Apr 2018 01:00 PM
RNS
Appointment of US-based Chief Medical Officer
26 Mar 2018 07:00 AM
RNS
Product Development Update
01 Mar 2018 07:00 AM
RNS
Block Listing Review and TVR
16 Feb 2018 07:00 AM
RNS
Block Listing Application
13 Feb 2018 10:00 AM
RNS
Positive pre-clinical data in nerve injury
26 Jan 2018 07:00 AM
RNS
Phase II stroke data presented at AHA conference
23 Jan 2018 11:06 AM
RNS
Approval of Share Capital Reorganisation
11 Jan 2018 07:00 AM
RNS
Further re Share Capital Reorganisation
05 Jan 2018 07:00 AM
RNS
Proposed Share Capital Reorganisation
14 Dec 2017 07:00 AM
RNS
Interim results
14 Dec 2017 07:00 AM
RNS
Stroke clinical trial regulatory approval in US

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

It listed on AIM in 2006 under the ticker RENE.

UK 100

Latest directors dealings